Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast - 2034

Key Highlights

• According to estimates in 2022, the total diagnosed prevalent cases of Cough in IPF in the 7MM were nearly 148,000 in 2022, which is expected to increase by 2034 due to improved awareness, aging populations, and advancements in diagnostic capabilities.
• As per the analysis, the diagnosed prevalent cases of cough in IPF in the US were reported to be highest with approximately 75 thousand cases, in 2022. These cases are anticipated to rise in the future.
• Among EU4 and the UK, the diagnosed prevalent cases of cough in IPF were highest in the UK with around 12 thousand cases, and lowest in Germany with approximately 8 thousand cases in 2022.

The “Cough in Idiopathic pulmonary fibrosis (IPF) - Epidemiology - 2034” report delivers an in-depth understanding of the Cough in Idiopathic pulmonary fibrosis (IPF), historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Disease Understanding and Diagnosis Algorithm

Cough in Idiopathic pulmonary fibrosis (IPF) Overview

Cough in idiopathic pulmonary fibrosis (IPF) serves as a complex marker of disease progression and symptom burden. It not only reflects the underlying fibrotic process but also contributes to decreased quality of life and increased mortality. Understanding the nuances of cough in IPF involves exploring its multifactorial origins, which can include mechanical distortion of the airways, neurogenic factors, and inflammation.

Cough in Idiopathic pulmonary fibrosis (IPF) Diagnosis

The clinical diagnosis of Cough in IPF is done by identifying characteristic symptoms, a detailed patient history, a thorough clinical evaluation, chest x-rays (radiography), computed tomography (CT) scans, pulmonary function tests, blood tests, and the surgical removal and microscopic examination of lung tissue (lung biopsy). Diagnosing cough in IPF can be challenging due to its nonspecific nature. Integration of high-resolution imaging and pulmonary function tests aids in accurate diagnosis.

Cough in Idiopathic pulmonary fibrosis (IPF) Epidemiology

As the market is derived using the patient-based model, the Cough in Idiopathic pulmonary fibrosis (IPF) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Idiopathic pulmonary fibrosis (IPF), and Total Diagnosed Prevalent Cases of Cough in Idiopathic pulmonary fibrosis (IPF) in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

• In 2022, the 7MM recorded approximately 184,000 diagnosed prevalent cases of IPF, projected to rise by 2034. Specifically, the US saw around 95,000 cases, with a temporary decline attributed to COVID, though a recovery was anticipated by 2023. Diagnosed Prevalent Cases of Cough in IPF accounted for 80% of these cases.
• The United States has the highest diagnosed prevalent cases of cough in IPF among the 7MM countries, comprising 51% of the total 7MM cases.
• Among EU4 and the UK, the diagnosed prevalent cases of IPF were highest in the UK with around 16 thousand cases, followed by France with approximately 15.5 thousand cases, while Germany accounted for the least cases with approximately 11 thousand in 2022.
• EU4 and the UK accounted for approximately 55,100 diagnosed prevalent cases of cough in IPF, in 2022. These cases are expected to rise during the study period.
• In 2022, the total diagnosed prevalent cases of IPF in Japan were found to be approximately 21,000 among which cough in IPF cases accounted for approximately 16,800 cases.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Cough in Idiopathic pulmonary fibrosis (IPF) evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, along with challenges related to accessibility, including KOL from Albert Einstein College of Medicine, New York; Louis Pradel Hospital, Hospices Civils de Lyon, France; University of Modena and Reggio Emilia, Italy; Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK; Graduate School of Medicine, Kyoto University, Kyoto, and others.

The analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Cough in Idiopathic pulmonary fibrosis (IPF), explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Cough in Idiopathic pulmonary fibrosis (IPF) Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Total Diagnosed Prevalence of Idiopathic pulmonary fibrosis (IPF)
• Total Diagnosed Prevalence of Cough in Idiopathic pulmonary fibrosis (IPF)

Cough in Idiopathic pulmonary fibrosis (IPF) Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Cough in Idiopathic pulmonary fibrosis (IPF) Epidemiology Segmentation

Key Questions

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Cough in Idiopathic pulmonary fibrosis (IPF)? What will be the growth opportunities across the 7MM concerning the patient population of Cough in Idiopathic pulmonary fibrosis (IPF)?
• What is the historical and forecasted Cough in Idiopathic pulmonary fibrosis (IPF) patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which country is more prevalent for Cough in Idiopathic pulmonary fibrosis (IPF) and why?
• What factors are affecting the diagnosis of the indication?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Cough in Idiopathic pulmonary fibrosis (IPF) prevalence cases in varying geographies over the coming years.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Cough in Idiopathic pulmonary fibrosis (IPF) Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Cough in Idiopathic pulmonary fibrosis (IPF) cases in 2023?

The highest cases of Cough in Idiopathic pulmonary fibrosis (IPF) was found in the UK, among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Cough in Idiopathic pulmonary fibrosis (IPF) cases in 2023?

The highest cases of Cough in Idiopathic pulmonary fibrosis (IPF) were found in the US among the 7MM in 2023.